Upstream Bio to Report Phase 2 Trial Results for Severe Asthma Drug

Webcast scheduled for Wednesday, February 11, 2026 at 8:00 a.m. ET

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

Upstream Bio, a clinical-stage biotech company, announced it will report top-line results from the Phase 2 VALIANT trial of its drug verekitug, an antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in patients with severe asthma. The VALIANT trial evaluated the safety and efficacy of verekitug over 24 to 60 weeks of treatment in 478 patients.

Why it matters

Severe asthma is a debilitating condition that affects millions globally and current treatments often fall short. Verekitug represents a novel approach by targeting the TSLP receptor, which plays a key role in driving the inflammatory response. Positive results from this Phase 2 trial could pave the way for further development and potentially offer a new treatment option for patients with severe asthma.

The details

The VALIANT trial was a global, randomized, double-blind, placebo-controlled, dose-ranging study that evaluated three different dosing regimens of verekitug compared to placebo. Participants were randomized into four groups receiving either 100 mg every 24 weeks, 400 mg every 24 weeks, 100 mg every 12 weeks, or placebo, administered subcutaneously.

  • The VALIANT trial enrolled 478 patients with severe asthma.
  • The trial evaluated verekitug for a minimum of 24 weeks and up to 60 weeks of treatment.
  • Upstream Bio will report the top-line results from the VALIANT trial on Wednesday, February 11, 2026 at 8:00 a.m. ET.

The players

Upstream Bio, Inc.

A clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.

Verekitug

Upstream Bio's monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, a clinically validated driver of inflammatory response.

Got photos? Submit your photos here. ›

What’s next

Pending the results of the VALIANT trial, Upstream Bio may move forward with further development of verekitug for the treatment of severe asthma.

The takeaway

The VALIANT trial represents an important milestone in the development of a novel therapy targeting the TSLP receptor, which could offer a new treatment option for the millions of patients suffering from debilitating severe asthma.